Sanofi (SNY) Competitors

$42.42 -0.44 (-1.03%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$42.78 +0.36 (+0.85%)

As of 06:54 AM Eastern

SNY vs. AZN, NVS, NVO, GSK, and TAK

Should you buy Sanofi stock or one of its competitors? MarketBeat compares Sanofi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sanofi include Astrazeneca (AZN), Novartis (NVS), Novo Nordisk A/S (NVO), GSK (GSK), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceutical products" industry.

How does Sanofi compare to Astrazeneca?

Sanofi (NASDAQ:SNY) and Astrazeneca (NYSE:AZN) are both large-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Astrazeneca has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.10	$8.84B	$3.58	11.85
Astrazeneca	$58.74B	4.96	$10.23B	$6.66	28.18

Sanofi has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Sanofi presently has a consensus target price of $51.00, indicating a potential upside of 20.23%. Astrazeneca has a consensus target price of $205.33, indicating a potential upside of 9.39%. Given Sanofi's higher possible upside, equities research analysts plainly believe Sanofi is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

14.0% of Sanofi shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Astrazeneca had 11 more articles in the media than Sanofi. MarketBeat recorded 16 mentions for Astrazeneca and 5 mentions for Sanofi. Astrazeneca's average media sentiment score of 1.02 beat Sanofi's score of 0.74 indicating that Astrazeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Astrazeneca has a net margin of 17.19% compared to Sanofi's net margin of 16.95%. Astrazeneca's return on equity of 30.86% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
Astrazeneca	17.19%	30.86%	12.68%

Sanofi pays an annual dividend of $1.77 per share and has a dividend yield of 4.2%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.3%. Sanofi pays out 49.4% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Astrazeneca beats Sanofi on 13 of the 19 factors compared between the two stocks.

How does Sanofi compare to Novartis?

Novartis (NYSE:NVS) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Novartis currently has a consensus target price of $141.20, suggesting a potential downside of 5.69%. Sanofi has a consensus target price of $51.00, suggesting a potential upside of 20.23%. Given Sanofi's stronger consensus rating and higher possible upside, analysts plainly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Sanofi pays an annual dividend of $1.77 per share and has a dividend yield of 4.2%. Novartis pays out 44.1% of its earnings in the form of a dividend. Sanofi pays out 49.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

In the previous week, Novartis had 12 more articles in the media than Sanofi. MarketBeat recorded 17 mentions for Novartis and 5 mentions for Sanofi. Sanofi's average media sentiment score of 0.74 beat Novartis' score of 0.16 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanofi	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.24	$13.98B	$6.98	21.45
Sanofi	$49.35B	2.10	$8.84B	$3.58	11.85

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
Sanofi	16.95%	13.39%	7.58%

13.1% of Novartis shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Novartis beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Sanofi compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Novo Nordisk A/S has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Novo Nordisk A/S currently has a consensus target price of $65.56, suggesting a potential upside of 39.12%. Sanofi has a consensus target price of $51.00, suggesting a potential upside of 20.23%. Given Novo Nordisk A/S's higher probable upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40

In the previous week, Novo Nordisk A/S had 58 more articles in the media than Sanofi. MarketBeat recorded 63 mentions for Novo Nordisk A/S and 5 mentions for Sanofi. Sanofi's average media sentiment score of 0.74 beat Novo Nordisk A/S's score of 0.49 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	24 Very Positive mention(s)	11 Positive mention(s)	14 Neutral mention(s)	7 Negative mention(s)	5 Very Negative mention(s)	Neutral
Sanofi	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.50	$15.51B	$4.26	11.06
Sanofi	$49.35B	2.10	$8.84B	$3.58	11.85

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Sanofi	16.95%	13.39%	7.58%

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.7%. Sanofi pays an annual dividend of $1.77 per share and has a dividend yield of 4.2%. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Sanofi pays out 49.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Novo Nordisk A/S beats Sanofi on 11 of the 19 factors compared between the two stocks.

How does Sanofi compare to GSK?

Sanofi (NASDAQ:SNY) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Sanofi pays an annual dividend of $1.77 per share and has a dividend yield of 4.2%. GSK pays an annual dividend of $1.88 per share and has a dividend yield of 3.7%. Sanofi pays out 49.4% of its earnings in the form of a dividend. GSK pays out 48.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Sanofi has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, GSK has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Sanofi has higher revenue and earnings than GSK. Sanofi is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.10	$8.84B	$3.58	11.85
GSK	$43.07B	2.40	$7.54B	$3.85	13.23

In the previous week, GSK had 3 more articles in the media than Sanofi. MarketBeat recorded 8 mentions for GSK and 5 mentions for Sanofi. Sanofi's average media sentiment score of 0.74 beat GSK's score of 0.12 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sanofi presently has a consensus target price of $51.00, suggesting a potential upside of 20.23%. GSK has a consensus target price of $53.00, suggesting a potential upside of 4.03%. Given Sanofi's stronger consensus rating and higher probable upside, equities analysts plainly believe Sanofi is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90

GSK has a net margin of 17.82% compared to Sanofi's net margin of 16.95%. GSK's return on equity of 44.28% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
GSK	17.82%	44.28%	11.49%

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

GSK beats Sanofi on 11 of the 19 factors compared between the two stocks.

How does Sanofi compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Sanofi has a net margin of 16.95% compared to Takeda Pharmaceutical's net margin of 2.58%. Sanofi's return on equity of 13.39% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	2.58%	10.60%	5.21%
Sanofi	16.95%	13.39%	7.58%

Sanofi has a consensus price target of $51.00, suggesting a potential upside of 20.23%. Given Sanofi's higher probable upside, analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Takeda Pharmaceutical has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$30.09B	1.76	$712.33M	$0.24	69.27
Sanofi	$49.35B	2.10	$8.84B	$3.58	11.85

In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Sanofi. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 5 mentions for Sanofi. Sanofi's average media sentiment score of 0.74 beat Takeda Pharmaceutical's score of -0.21 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanofi	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Takeda Pharmaceutical pays an annual dividend of $0.50 per share and has a dividend yield of 3.0%. Sanofi pays an annual dividend of $1.77 per share and has a dividend yield of 4.2%. Takeda Pharmaceutical pays out 208.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 49.4% of its earnings in the form of a dividend. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Sanofi beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks.

Get Sanofi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNY vs. The Competition

Export

Metric	Sanofi	Large Cap Pharma Industry	Medical Sector	NASDAQ Exchange
Market Cap	$104.54B	$293.92B	$6.30B	$12.20B
Dividend Yield	4.12%	2.81%	2.79%	5.30%
P/E Ratio	11.85	26.54	21.03	25.58
Price / Sales	2.10	4.93	548.94	78.80
Price / Cash	6.07	12.59	42.94	55.34
Price / Book	1.21	7.03	9.84	6.66
Net Income	$8.84B	$11.61B	$3.55B	$333.63M
7 Day Performance	-1.76%	1.69%	-0.52%	-0.12%
1 Month Performance	-10.96%	-0.83%	1.21%	3.93%
1 Year Performance	-13.80%	30.36%	41.24%	36.07%

Sanofi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNY Sanofi	4.1973 of 5 stars	$42.42 -1.0%	$51.00 +20.2%	-15.1%	$104.54B	$49.35B	11.85	74,846	Analyst Revision
AZN Astrazeneca	3.8923 of 5 stars	$181.91 -0.5%	$205.33 +12.9%	+38.6%	$283.58B	$58.74B	19.75	96,100	Positive News Analyst Forecast
NVS Novartis	3.291 of 5 stars	$145.11 -0.6%	$141.20 -2.7%	+40.1%	$278.65B	$54.53B	20.79	75,267	Analyst Revision
NVO Novo Nordisk A/S	4.6292 of 5 stars	$46.34 +0.6%	$65.56 +41.5%	-27.9%	$205.70B	$46.80B	10.88	69,505	Trending News Analyst Forecast Analyst Revision
GSK GSK	3.2191 of 5 stars	$49.82 -1.2%	$53.00 +6.4%	+40.1%	$102.29B	$43.07B	12.95	66,841	Dividend Cut

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNY) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanofi (SNY) Competitors